Pharmacogenomics Market Size, Share, Analysis By Products And Services, By Technology, Gel Electrophoresis) By Application, And By End User Forecasts To 2027

Increasing prevalence of various chronic diseases, rising awareness and need for personalized medicines and therapies, and increasing research and development projects in the field are key factors driving market revenue growth.

Market Size - USD 6,188.3 Million in 2020, Market Growth - CAGR of 8.4%, Market Trends - Rising investments in research, development, and launch of personalized drugs to ensure appropriate outcome of taking drugs.

The global pharmacogenomics (PGx) market size is expected to reach USD 11.86 Billion in 2028, and register a CAGR of 8.4% during the forecast period. Growing demand for pharmacogenomics to develop drugs and treatment for various chronic diseases including cardiovascular diseases (CVD) and neurology, constant technological advancements in pharmaceutical sector, investments to ensure efficiency and safety of drugs, clubbed with increasing need for personalized drugs and treatment are some of the major factors expected to drive growth of the global pharmacogenomics (PGx) market.

Pharmacogenomics is a combined study of pharmacology and genomics which defines effects of genes on an individual’s response to specific drugs. This helps to develop safe and effective medications and measured doses that can be customized according to individual’s genetic makeup.

Some Key Findings From the Report:

Among the application segments, the oncology segment accounted for the largest revenue share of 32.1% in 2020.
North America accounted for major revenue share in 2020, followed by Europe market.
The Asia Pacific market size was USD 1,423.3 Million in 2020, due to increasing spending on R&D of personalized medication in order to cater to individual patients by understanding genomics.
Key players profiled in the report include Abbott Laboratories, Admera Health, LLC, Agena Biosciences, Inc., Cancer Genetics, Inc., Dynamic DNA Laboratories, F. Hoffmann-La Roche Ltd, geneOmbio Technologies Pvt. Ltd., Genomic Health, Inc., Illumina, Inc., and Laboratory Corporation of America Holdings. The market players have adopted various strategies including mergers, acquisitions, partnerships, and new product developments, among other strategies, to stay ahead of the competition and expand market footprint.
In February 2020, Euformatics and bio.logis digital health GmbH formed alliance to work together on pharmacogenomics. This alliance was made to combine their respective informatics technologies to provide pharmacogenomic information for patients undergoing next-generation sequencing-based genetic testing.

For the purpose of this report, the global pharmacogenomics (PGx) market is segmented on the basis of products and services, technology, application, end use, and region:

Products and Services Outlook (Revenue, USD Billion; 2018 - 2028)

Products
Kits
Assay & Reagents
Instruments
Software
Services
Genotyping
SNP Identification
Pharmacogenetics Testing
Other Services

Technology Outlook (Revenue, USD Billion; 2018 - 2028)

Polymerase Chain Reaction (PCR)
Real Time PCR
qPCR
Digital PCR
DNA Sequencing/Next Generation Sequencing (NGS)
Nucleic Acid Amplification Tests (NAATs)
Mass Spectrometry
Gel Electrophoresis
Hybridization
Fluorescence In Situ Hybridization (FISH)
Chromogenic In Situ Hybridization (CISH)
Others
Microarray
Others

Application Outlook (Revenue, USD Billion; 2018 - 2028)

Oncology
Infectious Diseases
Neurology/Psychiatry
Cardiovascular
Others

End Use Outlook (Revenue, USD Billion; 2018 - 2028)

Research Organizations
Pharmaceutical Companies
Diagnostic Centers
Others

Region Outlook (Revenue, USD Billion; 2018 - 2028)

North America
US
Canada
Mexico
Europe
Germany
UK
France
Italy
Spain
Benelux
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Rest of Asia Pacific
Latin America
Brazil
Rest of Latin America
Middle East and Africa
Saudi Arabia
UAE
South Africa
Rest of Middle East & Africa

Reasons to Buy the Report

A robust analysis and estimation of the Pharmacogenomics (PGx) Market with four levels of quality check - in-house database, expert interviews, governmental regulation, and a forecast specifically done through time series analysis
A holistic competitive landscape of the all the major players in the Pharmacogenomics (PGx) Market. The report covers their market shares, strategic initiatives, new product launches, R&D expenditure, M&As, Joint ventures, expansionary plans, product wise metric space analysis and key developments
Go-to-market strategies specifically formulated in line with location analysis which takes into the factors such as government regulations, supplier mapping, supply chain obstacles, and feedback from local vendors
Most deep dive segmental bifurcation available currently in the market. Our stellar methodology helps us understand the overall gamut of the supply chain and will help you explain the current market dynamics
Special focus given on vendor landscape, supplier portfolio, customer mapping, production capacity, and yearly capacity utilization

Chapter 1. Market Synopsis

1.1. Market Definition
1.2. Research Scope & Premise
1.3. Methodology
1.4. Market Estimation Technique

Chapter 2. Executive Summary

2.1. Summary Snapshot, 2019 - 2027

Chapter 3. Indicative Metrics

3.1. Increasing R&D Investment
3.2. Surge in Usage of Pharmacogenomics for Drug Discovery and Development
3.3. Increasing Resistance and Adverse Drug Reactions of Other Therapies

Chapter 4. Pharmacogenomics (PGx) Segmentation & Impact Analysis

4.1. Pharmacogenomics (PGx) Segmentation Analysis
4.2. Pharmacogenomics (PGx) Market Value Chain Analysis, 2017-2027
4.3. Regulatory framework
4.4. Pharmacogenomics (PGx) Market Impact Analysis
4.4.1. Market driver analysis
4.4.1.1. Growing demand for personalized therapy
4.4.1.2. Increasing prevalence of target chronic diseases
4.4.1.3. Technological Advancements
4.4.1.4. Favorable government initiatives
4.4.1.5. Availability of financial support for research and development
4.4.2. Market restraint analysis
4.4.2.1. High Costs
4.4.2.2. Lack of High Complexity Testing Centers
4.5. Key opportunities prioritized
4.6. Pharmacogenomics (PGx) Pricing Analysis
4.7. Industry analysis - Porter's
4.8. Pharmacogenomics (PGx) PESTEL Analysis

Chapter 5. Pharmacogenomics (PGx) Market By Products & Services Insights & Trends

5.1. Pharmacogenomics (PGx) Products & Services dynamics & Market Share, 2019 & 2027
5.2. Products
5.2.1. Market estimates and forecast, 2017 - 2027 (USD Million)
5.2.2. Market estimates and forecast, by region, 2017 - 2027 (USD Million)
5.2.3. Kits
5.2.3.1. Market estimates and forecast, 2017 - 2027 (USD Million)
5.2.3.2. Market estimates and forecast, by region, 2017 - 2027 (USD Million)
5.2.4. Assay & Reagents
5.2.4.1. Market estimates and forecast, 2017 - 2027 (USD Million)
5.2.4.2. Market estimates and forecast, by region, 2017 - 2027 (USD Million)
5.2.5. Instruments
5.2.5.1. Market estimates and forecast, 2017 - 2027 (USD Million)
5.2.5.2. Market estimates and forecast, by region, 2017 - 2027 (USD Million)
5.2.6. Software
5.2.6.1. Market estimates and forecast, 2017 - 2027 (USD Million)
5.2.6.2. Market estimates and forecast, by region, 2017 - 2027 (USD Million)
5.3. Services
5.3.1. Market estimates and forecast, 2017 - 2027 (USD Million)
5.3.2. Market estimates and forecast, by region, 2017 - 2027 (USD Million)
5.3.3. Genotyping
5.3.3.1. Market estimates and forecast, 2017 - 2027 (USD Million)
5.3.3.2. Market estimates and forecast, by region, 2017 - 2027 (USD Million)
5.3.4. SNP Identification
5.3.4.1. Market estimates and forecast, 2017 - 2027 (USD Million)
5.3.4.2. Market estimates and forecast, by region, 2017 - 2027 (USD Million)
5.3.5. Pharmacogenetic Testing
5.3.5.1. Market estimates and forecast, 2017 - 2027 (USD Million)
5.3.5.2. Market estimates and forecast, by region, 2017 - 2027 (USD Million)
5.3.6. Other Services
5.3.6.1. Market estimates and forecast, 2017 - 2027 (USD Million)
5.3.6.2. Market estimates and forecast, by region, 2017 - 2027 (USD Million)

Chapter 6. Pharmacogenomics (PGx) Market By Technology Insights & Trends

6.1. Pharmacogenomics (PGx) Technology dynamics & Market Share, 2019 & 2027
6.2. Polymerase Chain Reaction (PCR)
6.2.1. Market estimates and forecast, 2017 - 2027 (USD Million)
6.2.2. Market estimates and forecast, by region, 2017 - 2027 (USD Million)
6.2.3. Real Time PCR
6.2.3.1. Market estimates and forecast, 2017 - 2027 (USD Million)
6.2.3.2. Market estimates and forecast, by region, 2017 - 2027 (USD Million)
6.2.4. qPCR
6.2.4.1. Market estimates and forecast, 2017 - 2027 (USD Million)
6.2.4.2. Market estimates and forecast, by region, 2017 - 2027 (USD Million)
6.2.5. Digital PCR
6.2.5.1. Market estimates and forecast, 2017 - 2027 (USD Million)
6.2.5.2. Market estimates and forecast, by region, 2017 - 2027 (USD Million)
6.3. DNA Sequencing/Next Generation Sequencing (NGS)
6.3.1. Market estimates and forecast, 2017 - 2027 (USD Million)
6.3.2. Market estimates and forecast, by region, 2017 - 2027 (USD Million)
6.4. Nucleic Acid Amplification Tests (NAATs)
6.4.1. Market estimates and forecast, 2017 - 2027 (USD Million)
6.4.2. Market estimates and forecast, by region, 2017 - 2027 (USD Million)
6.5. Mass Spectrometry
6.5.1. Market estimates and forecast, 2017 - 2027 (USD Million)
6.5.2. Market estimates and forecast, by region, 2017 - 2027 (USD Million)
6.6. Gel Electrophoresis
6.6.1. Market estimates and forecast, 2017 - 2027 (USD Million)
6.6.2. Market estimates and forecast, by region, 2017 - 2027 (USD Million)
6.7. Hybridization
6.7.1. Market estimates and forecast, 2017 - 2027 (USD Million)
6.7.2. Market estimates and forecast, by region, 2017 - 2027 (USD Million)
6.7.3. Fluorescence In Situ Hybridization (FISH)
6.7.3.1. Market estimates and forecast, 2017 - 2027 (USD Million)
6.7.3.2. Market estimates and forecast, by region, 2017 - 2027 (USD Million)
6.7.4. Chromogenic In Situ Hybridization (CISH)
6.7.4.1. Market estimates and forecast, 2017 - 2027 (USD Million)
6.7.4.2. Market estimates and forecast, by region, 2017 - 2027 (USD Million)
6.7.5. Others
6.7.5.1. Market estimates and forecast, 2017 - 2027 (USD Million)
6.7.5.2. Market estimates and forecast, by region, 2017 - 2027 (USD Million)
6.8. Microarray
6.8.1. Market estimates and forecast, 2017 - 2027 (USD Million)
6.8.2. Market estimates and forecast, by region, 2017 - 2027 (USD Million)
6.9. Others
6.9.1. Market estimates and forecast, 2017 - 2027 (USD Million)
6.9.2. Market estimates and forecast, by region, 2017 - 2027 (USD Million)

Chapter 7. Pharmacogenomics (PGx) Market By Application Insights & Trends

7.1. Pharmacogenomics (PGx) Application dynamics & Market Share, 2019 & 2027
7.2. Oncology
7.2.1. Market estimates and forecast, 2017 - 2027 (USD Million)
7.2.2. Market estimates and forecast, by region, 2017 - 2027 (USD Million)
7.3. Infectious Diseases
7.3.1. Market estimates and forecast, 2017 - 2027 (USD Million)
7.3.2. Market estimates and forecast, by region, 2017 - 2027 (USD Million)
7.4. Neurology/Psychiatry
7.4.1. Market estimates and forecast, 2017 - 2027 (USD Million)
7.4.2. Market estimates and forecast, by region, 2017 - 2027 (USD Million)
7.5. Cardiovascular
7.5.1. Market estimates and forecast, 2017 - 2027 (USD Million)
7.5.2. Market estimates and forecast, by region, 2017 - 2027 (USD Million)
7.6. Others
7.6.1. Market estimates and forecast, 2017 - 2027 (USD Million)
7.6.2. Market estimates and forecast, by region, 2017 - 2027 (USD Million)

Chapter 8. Pharmacogenomics (PGx) Market By End Use Insights & Trends

8.1. Pharmacogenomics (PGx) End Use dynamics & Market Share, 2019 & 2027
8.2. Research Organisation
8.2.1. Market estimates and forecast, 2017 - 2027 (USD Million)
8.2.2. Market estimates and forecast, by region, 2017 - 2027 (USD Million)
8.3. Pharmaceutical Companies
8.3.1. Market estimates and forecast, 2017 - 2027 (USD Million)
8.3.2. Market estimates and forecast, by region, 2017 - 2027 (USD Million)
8.4. Diagnostic Centers
8.4.1. Market estimates and forecast, 2017 - 2027 (USD Million)
8.4.2. Market estimates and forecast, by region, 2017 - 2027 (USD Million)
8.5. Others
8.5.1. Market estimates and forecast, 2017 - 2027 (USD Million)
8.5.2. Market estimates and forecast, by region, 2017 - 2027 (USD Million)

Chapter 9. Pharmacogenomics (PGx) Market Regional Outlook

9.1. Pharmacogenomics (PGx) Market share by region, 2019 & 2027
9.2. North America
9.2.1. North America Pharmacogenomics (PGx) Market estimates and forecast, 2017 - 2027, (USD Million)
9.2.2. North America Pharmacogenomics (PGx) Market estimates and forecast by Products & Services, 2017 - 2027, (USD Million)
9.2.3. North America Pharmacogenomics (PGx) Market estimates and forecast by Technology, 2017 - 2027, (USD Million)
9.2.4. North America Pharmacogenomics (PGx) Market estimates and forecast by Application, 2017 - 2027, (USD Million)
9.2.5. North America Pharmacogenomics (PGx) Market estimates and forecast by End Use, 2017 - 2027, (USD Million)
9.2.6. U.S.
9.2.6.1. U.S. Pharmacogenomics (PGx) Market estimates and forecast, 2017 - 2027, (USD Million)
9.2.6.2. U.S. Pharmacogenomics (PGx) Market estimates and forecast by Products & Services, 2017 - 2027, (USD Million)
9.2.6.3. U.S. Pharmacogenomics (PGx) Market estimates and forecast by Technology, 2017 - 2027, (USD Million)
9.2.6.4. U.S. Pharmacogenomics (PGx) Market estimates and forecast by Application, 2017 - 2027, (USD Million)
9.2.6.5. U.S. Pharmacogenomics (PGx) Market estimates and forecast by End Use, 2017 - 2027, (USD Million)
9.2.7. Canada
9.2.7.1. Canada Pharmacogenomics (PGx) Market estimates and forecast, 2017 - 2027, (USD Million)
9.2.7.2. Canada Pharmacogenomics (PGx) Market estimates and forecast by Products & Services, 2017 - 2027, (USD Million)
9.2.7.3. Canada Pharmacogenomics (PGx) Market estimates and forecast by Technology, 2017 - 2027, (USD Million)
9.2.7.4. Canada Pharmacogenomics (PGx) Market estimates and forecast by Application, 2017 - 2027, (USD Million)
9.2.7.5. Canada Pharmacogenomics (PGx) Market estimates and forecast by End Use, 2017 - 2027, (USD Million)
9.3. Europe
9.3.1. Europe Pharmacogenomics (PGx) Market estimates and forecast, 2017 - 2027, (USD Million)
9.3.2. Europe Pharmacogenomics (PGx) Market estimates and forecast by Products & Services, 2017 - 2027, (USD Million)
9.3.3. Europe Pharmacogenomics (PGx) Market estimates and forecast by Technology, 2017 - 2027, (USD Million)
9.3.4. Europe Pharmacogenomics (PGx) Market estimates and forecast by Application, 2017 - 2027, (USD Million)
9.3.5. Europe Pharmacogenomics (PGx) Market estimates and forecast by End Use, 2017 - 2027, (USD Million)
9.3.6. Germany
9.3.6.1. Germany Pharmacogenomics (PGx) Market estimates and forecast, 2017 - 2027, (USD Million)
9.3.6.2. Germany Pharmacogenomics (PGx) Market estimates and forecast by Products & Services, 2017 - 2027, (USD Million)
9.3.6.3. Germany Pharmacogenomics (PGx) market estimates and forecast by Technology, 2017 - 2027, (USD Million)
9.3.6.4. Germany Pharmacogenomics (PGx) Market estimates and forecast by Application, 2017 - 2027, (USD Million)
9.3.6.5. Germany Pharmacogenomics (PGx) market estimates and forecast by End Use, 2017 - 2027, (USD Million)
9.3.7. France
9.3.7.1. France Pharmacogenomics (PGx) Market estimates and forecast, 2017 - 2027, (USD Million)
9.3.7.2. France Pharmacogenomics (PGx) Market estimates and forecast by Products & Services, 2017 - 2027, (USD Million)
9.3.7.3. France Pharmacogenomics (PGx) market estimates and forecast by Technology, 2017 - 2027, (USD Million)
9.3.7.4. France Pharmacogenomics (PGx) Market estimates and forecast by Application, 2017 - 2027, (USD Million)
9.3.7.5. France Pharmacogenomics (PGx) market estimates and forecast by End Use, 2017 - 2027, (USD Million)
9.3.8. U.K.
9.3.8.1. U.K Pharmacogenomics (PGx) market estimates and forecast, 2017 - 2027, (USD Million)
9.3.8.2. U.K Pharmacogenomics (PGx) market estimates and forecast by Products & Services, 2017 - 2027, (USD Million)
9.3.8.3. U.K. Pharmacogenomics (PGx) market estimates and forecast by Technology, 2017 - 2027, (USD Million)
9.3.8.4. U.K. Pharmacogenomics (PGx) Market estimates and forecast by Application, 2017 - 2027, (USD Million)
9.3.8.5. U.K. Pharmacogenomics (PGx) market estimates and forecast by End Use, 2017 - 2027, (USD Million)
9.3.9. Rest of Europe
9.3.9.1. Rest of Europe Pharmacogenomics (PGx) market estimates and forecast, 2017 - 2027, (USD Million)
9.3.9.2. Rest of Europe Pharmacogenomics (PGx) market estimates and forecast by Products & Services, 2017 - 2027, (USD Million)
9.3.9.3. Rest of Europe Pharmacogenomics (PGx) market estimates and forecast by Technology, 2017 - 2027, (USD Million)
9.3.9.4. Rest of Europe Pharmacogenomics (PGx) Market estimates and forecast by Application, 2017 - 2027, (USD Million)
9.3.9.5. Rest of Europe Pharmacogenomics (PGx) market estimates and forecast by End Use, 2017 - 2027, (USD Million)
9.4. Asia Pacific
9.4.1. Asia Pacific Pharmacogenomics (PGx) market estimates and forecast, 2017 - 2027, (USD Million)
9.4.2. Asia Pacific Pharmacogenomics (PGx) market estimates and forecast by Products & Services, 2017 - 2027, (USD Million)
9.4.3. Asia Pacific Pharmacogenomics (PGx) market estimates and forecast by Technology, 2017 - 2027, (USD Million)
9.4.4. Asia Pacific Pharmacogenomics (PGx) Market estimates and forecast by Application, 2017 - 2027, (USD Million)
9.4.5. Asia Pacific Pharmacogenomics (PGx) market estimates and forecast by End Use, 2017 - 2027, (USD Million)
9.4.6. China
9.4.6.1. China Pharmacogenomics (PGx) market estimates and forecast, 2017 - 2027, (USD Million)
9.4.6.2. China Pharmacogenomics (PGx) market estimates and forecast by Products & Services, 2017 - 2027, (USD Million)
9.4.6.3. China Pharmacogenomics (PGx) market estimates and forecast by Technology, 2017 - 2027, (USD Million)
9.4.6.4. China Pharmacogenomics (PGx) Market estimates and forecast by Application, 2017 - 2027, (USD Million)
9.4.6.5. China Pharmacogenomics (PGx) market estimates and forecast by End Use, 2017 - 2027, (USD Million)
9.4.7. Japan
9.4.7.1. Japan Pharmacogenomics (PGx) market estimates and forecast, 2017 - 2027, (USD Million)
9.4.7.2. Japan Pharmacogenomics (PGx) market estimates and forecast by Products & Services, 2017 - 2027, (USD Million)
9.4.7.3. Japan Pharmacogenomics (PGx) market estimates and forecast by Technology, 2017 - 2027, (USD Million)
9.4.7.4. Japan Pharmacogenomics (PGx) Market estimates and forecast by Application, 2017 - 2027, (USD Million)
9.4.7.5. Japan Pharmacogenomics (PGx) market estimates and forecast by End Use, 2017 - 2027, (USD Million)
9.4.8. India
9.4.8.1. India Pharmacogenomics (PGx) market estimates and forecast, 2017 - 2027, (USD Million)
9.4.8.2. India Pharmacogenomics (PGx) market estimates and forecast by Products & Services, 2017 - 2027, (USD Million)
9.4.8.3. India Pharmacogenomics (PGx) market estimates and forecast by Technology, 2017 - 2027, (USD Million)
9.4.8.4. India Pharmacogenomics (PGx) Market estimates and forecast by Application, 2017 - 2027, (USD Million)
9.4.8.5. India Pharmacogenomics (PGx) market estimates and forecast by End Use, 2017 - 2027, (USD Million)
9.4.9. Rest of Asia Pacific
9.4.9.1. Rest of Asia Pacific Pharmacogenomics (PGx) market estimates and forecast, 2017 - 2027, (USD Million)
9.4.9.2. Rest of Asia Pacific Pharmacogenomics (PGx) market estimates and forecast by Products & Services, 2017 - 2027, (USD Million)
9.4.9.3. Rest of Asia Pacific Pharmacogenomics (PGx) market estimates and forecast by Technology, 2017 - 2027, (USD Million)
9.4.9.4. Rest of Asia Pacific Pharmacogenomics (PGx) Market estimates and forecast by Application, 2017 - 2027, (USD Million)
9.4.9.5. Rest of Asia Pacific Pharmacogenomics (PGx) market estimates and forecast by End Use, 2017 - 2027, (USD Million)
9.5. Middle East & Africa
9.5.1. Middle East and Africa Pharmacogenomics (PGx) market estimates and forecast, 2017 - 2027, (USD Million)
9.5.2. Middle East and Africa Pharmacogenomics (PGx) market estimates and forecast by Products & Services, 2017 - 2027, (USD Million)
9.5.3. Middle East and Africa Pharmacogenomics (PGx) market estimates and forecast by Technology, 2017 - 2027, (USD Million)
9.5.4. Middle East and Africa Pharmacogenomics (PGx) Market estimates and forecast by Application, 2017 - 2027, (USD Million)
9.5.5. Middle East and Africa Pharmacogenomics (PGx) market estimates and forecast by End Use, 2017 - 2027, (USD Million)
9.6. Latin America
9.6.1. Latin America Pharmacogenomics (PGx) market estimates and forecast, 2017 - 2027, (USD Million)
9.6.2. Latin America Pharmacogenomics (PGx) market estimates and forecast by Products & Services, 2017 - 2027, (USD Million)
9.6.3. Latin America Pharmacogenomics (PGx) market estimates and forecast by Technology, 2017 - 2027, (USD Million)
9.6.4. Latin America Pharmacogenomics (PGx) Market estimates and forecast by Application, 2017 - 2027, (USD Million)
9.6.5. Latin America Pharmacogenomics (PGx) market estimates and forecast by End Use, 2017 - 2027, (USD Million)
9.6.6. Brazil
9.6.6.1. Brazil Pharmacogenomics (PGx) market estimates and forecast, 2017 - 2027, (USD Million)
9.6.6.2. Brazil Pharmacogenomics (PGx) market estimates and forecast by Products & Services, 2017 - 2027, (USD Million)
9.6.6.3. Brazil Pharmacogenomics (PGx) market estimates and forecast by Technology, 2017 - 2027, (USD Million)
9.6.6.4. Brazil Pharmacogenomics (PGx) Market estimates and forecast by Application, 2017 - 2027, (USD Million)
9.6.6.5. Brazil Pharmacogenomics (PGx) market estimates and forecast by End Use, 2017 - 2027, (USD Million)

Chapter 10. Competitive Landscape

10.1. Market Revenue Share by Manufacturers
10.2. Manufacturing Cost Breakdown Analysis
10.3. Mergers & Acquisitions
10.4. Strategy Benchmarking
10.5. Vendor Landscape

Chapter 11. Company Profiles

11.1. Abbott Laboratories
11.1.1. Company Overview
11.1.2. Financial Performance
11.1.3. Product Length Benchmarking
11.1.4. Strategic Initiatives
11.2. Admera Health, LLC
11.2.1. Company Overview
11.2.2. Financial Performance
11.2.3. Product Length Benchmarking
11.2.4. Strategic Initiatives
11.3. Agena Biosciences, Inc.
11.3.1. Company Overview
11.3.2. Financial Performance
11.3.3. Product Length Benchmarking
11.3.4. Strategic Initiatives
11.4. Cancer Genetics, Inc.
11.4.1. Company Overview
11.4.2. Financial Performance
11.4.3. Product Length Benchmarking
11.4.4. Strategic Initiatives
11.5. Dynamic DNA Laboratories
11.5.1. Company Overview
11.5.2. Financial Performance
11.5.3. Product Length Benchmarking
11.5.4. Strategic Initiatives
11.6. F. Hoffmann-La Roche Ltd
11.6.1. Company Overview
11.6.2. Financial Performance
11.6.3. Product Length Benchmarking
11.6.4. Strategic Initiatives
11.7. geneOmbio Technologies Pvt Ltd.
11.7.1. Company Overview
11.7.2. Financial Performance
11.7.3. Product Length Benchmarking
11.7.4. Strategic Initiatives
11.8. Genomic Health, Inc.
11.8.1. Company Overview
11.8.2. Financial Performance
11.8.3. Product Length Benchmarking
11.8.4. Strategic Initiatives
11.9. Illumina, Inc.
11.9.1. Company Overview
11.9.2. Financial Performance
11.9.3. Product Length Benchmarking
11.9.4. Strategic Initiatives
11.10. Laboratory Corporation of America Holdings
11.10.1. Company Overview
11.10.2. Financial Performance
11.10.3. Product Length Benchmarking
11.10.4. Strategic Initiatives